Skip to main content

Peer Review reports

From: Budget impact analysis of the use of extended half-life recombinant factor VIII (efmoroctocog alfa) for the treatment of congenital haemophilia a: the Italian National Health System perspective

Original Submission
14 Jun 2017 Submitted Original manuscript
5 Feb 2018 Author responded Author comments - Valentina Lorenzoni
5 Sep 2017 Reviewed Reviewer Report - Peyman Eshghi
2 Jan 2018 Reviewed Reviewer Report - Marisa Santos
Resubmission - Version 2
5 Feb 2018 Submitted Manuscript version 2
5 Jun 2018 Author responded Author comments - Valentina Lorenzoni
7 Feb 2018 Reviewed Reviewer Report - Marisa Santos
Resubmission - Version 3
5 Jun 2018 Submitted Manuscript version 3
Publishing
15 Jul 2018 Editorially accepted
2 Aug 2018 Article published 10.1186/s12913-018-3398-x

You can find further information about peer review here.

Back to article page
\